KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Shares Outstanding (2020 - 2025)

Historic Shares Outstanding for AbCellera Biologics (ABCL) over the last 6 years, with Q3 2025 value amounting to $299.0 million.

  • AbCellera Biologics' Shares Outstanding rose 130.58% to $299.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $299.0 million, marking a year-over-year increase of 130.58%. This contributed to the annual value of $151.7 million for FY2019, which is N/A changed from last year.
  • Latest data reveals that AbCellera Biologics reported Shares Outstanding of $299.0 million as of Q3 2025, which was up 130.58% from $298.7 million recorded in Q2 2025.
  • In the past 5 years, AbCellera Biologics' Shares Outstanding registered a high of $299.0 million during Q3 2025, and its lowest value of $270.9 million during Q1 2021.
  • Moreover, its 5-year median value for Shares Outstanding was $289.2 million (2023), whereas its average is $288.8 million.
  • Its Shares Outstanding has fluctuated over the past 5 years, first soared by 8245.8% in 2021, then soared by 130.58% in 2025.
  • AbCellera Biologics' Shares Outstanding (Quarter) stood at $281.2 million in 2021, then increased by 1.64% to $285.8 million in 2022, then rose by 1.41% to $289.8 million in 2023, then increased by 1.86% to $295.2 million in 2024, then grew by 1.31% to $299.0 million in 2025.
  • Its Shares Outstanding was $299.0 million in Q3 2025, compared to $298.7 million in Q2 2025 and $298.4 million in Q1 2025.